Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BeyondSpring Inc. (BYSI : NSDQ)

• Company Description    BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. Number of Employees: 103

• Price / Volume Information    Yesterday's Closing Price: $1.23 Daily Weekly Monthly 20 Day Moving Average: 285,832 shares Shares Outstanding: 38.93 (millions) Market Capitalization: $47.88 (millions) Beta: 1.21 52 Week High: $33.00 52 Week Low: $1.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -38.50% -32.61% 12 Week -53.58% -49.64% Year To Date -72.85% -67.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 28 LIBERTY STREET 39TH FLOOR - NEW YORK,NY 10005 USA ph: 1-646-305-6387 fax: 1-646-882-4228 general@beyondspringpharma.com http://www.beyondspringpharma.com

• General Corporate Information    Officers Lan Huang - Chief Executive Officer & Chairperson Richard J. Daly - Chief Operating Officer Elizabeth Czerepak - Chief Financial Officer Gordon L. Schooley - Chief Regulatory Officer Ramon W. Mohanlal - Executive Vice President Peer Information BeyondSpring Inc. (CORR.) BeyondSpring Inc. (RSPI) BeyondSpring Inc. (CGXP) BeyondSpring Inc. (BGEN) BeyondSpring Inc. (GTBP) BeyondSpring Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G10830100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/21 Next Expected EPS Date: 06/15/22 Share - Related Items Shares Outstanding: 38.93 Most Recent Split Date: (:1) Beta: 1.21 Market Capitalization: $47.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.30 Price/Cash Flow: - Price / Sales: 35.44 EPS Growth vs. Year Ago Period: 53.85% vs. Previous Quarter: 48.94% Sales Growth vs. Year Ago Period: 87.78% vs. Previous Quarter: 0.30% ROE 03/31/22 - - 12/31/21 - -144.52 09/30/21 - -118.78 ROA 03/31/22 - - 12/31/21 - -71.38 09/30/21 - -73.17 Current Ratio 03/31/22 - - 12/31/21 - 4.96 09/30/21 - 5.10 Quick Ratio 03/31/22 - - 12/31/21 - 4.96 09/30/21 - 5.10 Operating Margin 03/31/22 - - 12/31/21 - -4,750.48 09/30/21 - -6,057.17 Net Margin 03/31/22 - - 12/31/21 - -4,750.48 09/30/21 - -6,057.17 Pre-Tax Margin 03/31/22 - - 12/31/21 - -4,784.46 09/30/21 - -6,141.49 Book Value 03/31/22 - - 12/31/21 - 0.54 09/30/21 - 0.86 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 20.68 09/30/21 - 13.67

Powered by Zacks Investment Research ©